Chatwal Monica S, Tanvetyanon Tawee
Division of Medicine, Division of Hematology/Oncology, University of South Florida/H Lee Moffitt Cancer Center, Tampa, FL 33612, USA.
Thoracic Oncology Department, H. Lee Moffitt Cancer Center, FL 33612, USA.
Immunotherapy. 2018 Apr;10(5):341-344. doi: 10.2217/imt-2017-0177.
Immunotherapy by checkpoint inhibitor is effective for a number of solid tumors including malignant mesothelioma. Studies utilizing single-agent PD-1 or PD-L1 inhibitor for mesothelioma have reported tumor response rates in approximately 10-20% of patients treated. Given the success of combining these agents with CTLA-4 inhibitor in melanoma, there is a strong rationale to study it in mesothelioma. Recently results from clinical trials investigating this approach have been released. Though limited by small sample size, the studies conclusively demonstrated feasibility and suggested a modestly higher tumor response rate than one would expect from treatment with single-agent PD-1 or PD-L1 inhibitor. Nevertheless, toxicity was also increased. Immunotherapy-related deaths due to encephalitis, renal failure and hepatitis were observed. Further studies are warranted.
通过检查点抑制剂进行的免疫疗法对包括恶性间皮瘤在内的多种实体瘤有效。利用单药PD-1或PD-L1抑制剂治疗间皮瘤的研究报告称，接受治疗的患者中约有10-20%出现肿瘤反应。鉴于这些药物与CTLA-4抑制剂联合用于黑色素瘤取得了成功，因此有充分的理由在间皮瘤中进行研究。最近，研究这种方法的临床试验结果已经公布。尽管受样本量小的限制，但这些研究最终证明了其可行性，并表明肿瘤反应率略高于单药PD-1或PD-L1抑制剂治疗的预期。然而，毒性也有所增加。观察到了因脑炎、肾衰竭和肝炎导致的与免疫疗法相关的死亡。有必要进行进一步的研究。
